Fredrick B Hagemeister

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy
    Fredrick B Hagemeister
    Department of Lymphoma Myeloma, Univeristy of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 1:120-5. 2003
  2. ncbi request reprint Hodgkin's lymphoma in younger patients: lessons learned on the road to success
    Fredrick B Hagemeister
    Department of Hematology, The University of Texas M D Anderson Cancer Center Houston, Texas 77030, USA
    Oncology (Williston Park) 21:434-40; discussion 441-2, 445-6. 2007
  3. ncbi request reprint Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:345-53. 2005
  4. ncbi request reprint An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 95:2534-8. 2002
  5. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
  6. ncbi request reprint Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma
    Amar Safdar
    Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Infect Dis 194:1394-7. 2006
  7. ncbi request reprint European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:1731-8. 2002
  8. pmc Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
    Peter McLaughlin
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, USA
    Blood 105:4573-5. 2005
  9. ncbi request reprint Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
  10. doi request reprint Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data
    Fredrick B Hagemeister
    Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 12:395-401. 2010

Detail Information

Publications29

  1. ncbi request reprint Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy
    Fredrick B Hagemeister
    Department of Lymphoma Myeloma, Univeristy of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 1:120-5. 2003
    ..Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care...
  2. ncbi request reprint Hodgkin's lymphoma in younger patients: lessons learned on the road to success
    Fredrick B Hagemeister
    Department of Hematology, The University of Texas M D Anderson Cancer Center Houston, Texas 77030, USA
    Oncology (Williston Park) 21:434-40; discussion 441-2, 445-6. 2007
    ....
  3. ncbi request reprint Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:345-53. 2005
    ....
  4. ncbi request reprint An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 95:2534-8. 2002
    ..The relative importance of prognostic factors in patients with early-stage Hodgkin disease remains controversial. The purpose of this study was to evaluate prognostic factors among patients who received chemotherapy before radiotherapy...
  5. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  6. ncbi request reprint Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma
    Amar Safdar
    Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Infect Dis 194:1394-7. 2006
    ..For each vaccine, the highest frequencies of increases in neutralizing antibody levels and the highest mean titers occurred in those given the 135- microg vaccine...
  7. ncbi request reprint European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:1731-8. 2002
    ....
  8. pmc Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
    Peter McLaughlin
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, USA
    Blood 105:4573-5. 2005
    ..MDS with features classically associated with DNA-damaging agents can occur following therapy with FND, with or without rituximab, and IFN-alpha...
  9. ncbi request reprint Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
    Nam H Dang
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    J Clin Oncol 22:4095-102. 2004
    ..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL...
  10. doi request reprint Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data
    Fredrick B Hagemeister
    Department of Lymphoma Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 12:395-401. 2010
    ....
  11. ncbi request reprint Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
    Nam H Dang
    MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 10:1513-8. 2003
    ..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
  12. ncbi request reprint Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:1294-302. 2006
    ..In this study, the authors assessed the incidence, presenting characteristics, and outcomes of patients with CLL/SLL who developed Hodgkin lymphoma (HL)...
  13. ncbi request reprint Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature
    Andres O Soriano
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 82:725-8. 2007
    ..A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease...
  14. ncbi request reprint Lymphoma of the colon
    Jorge Romaguera
    University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Gastroenterol 21:80-4. 2005
    ..Emphasis is on new entities such as mantle cell (MCL) and marginal zone (MZL) lymphomas. Presenting symptoms and signs are described where applicable and treatment and prognosis are covered briefly...
  15. ncbi request reprint Thalidomide for patients with recurrent lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1186-9. 2004
    ..However, its activity against other lymphoid tumors is unknown. The authors reported their experience with thalidomide in patients with recurrent/refractory non-Hodgkin lymphoma and in patients with Hodgkin disease...
  16. ncbi request reprint Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma
    Joseph D Khoury
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Surg Pathol 28:489-95. 2004
    ..Although the best terminology for these bone marrow lymphomas is uncertain, the aggressive clinical behavior of these neoplasms supports the need for intensive therapy...
  17. ncbi request reprint Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue
    Fredrick B Hagemeister
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 49:S13-20. 2002
    ..Finally, we have recently studied paclitaxel in combination with topotecan for relapsed and refractory aggressive lymphomas. These and newer combinations should be further developed to treat patients in relapse of aggressive lymphomas...
  18. ncbi request reprint Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
    Apostolia M Tsimberidou
    Department of Lymphoma and Myeloma, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:4351-7. 2002
    ..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND...
  19. ncbi request reprint Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
    Nam H Dang
    Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Br J Haematol 136:439-47. 2007
    ..Further studies of denileukin diftitox in combination with other agents are warranted in previously untreated and relapsed/refractory T-NHL...
  20. ncbi request reprint Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:1818-21. 2006
    ..The combination of fludarabine and paclitaxel has clinical activity in patients with recurrent low-grade NHL...
  21. ncbi request reprint Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 55:36-43. 2003
    ..Cardiac toxicity and second malignancies, particularly the incidence of solid tumors in terms of the RT field size treated, were also examined...
  22. ncbi request reprint Combination treatment approaches and novel therapies for lymphoma
    John P Leonard
    Clin Adv Hematol Oncol 5:4-20; quiz 1 p following 20. 2007
  23. ncbi request reprint Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  24. ncbi request reprint Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma
    Barbara Pro
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Lymphoma 47:481-5. 2006
    ..In these previously treated patients with NHL, a single dose of pegfilgrastim was effective in promoting neutrophil count recovery after paclitaxel and topotecan, and allowed patients to receive the next planned dose on time...
  25. ncbi request reprint Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma
    Yasuhiro Oki
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 104:781-7. 2005
    ..Oxaliplatin is a platinum derivative with a broad range of anticancer activity. The objective of the current Phase II trial was to investigate the activity of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma (NHL)...
  26. ncbi request reprint NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21
    Sara Frias
    Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, Livermore, California 94550, USA
    Cancer Res 63:44-51. 2003
    ....
  27. ncbi request reprint Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma
    John F Seymour
    Department of Haematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Clin Oncol 21:2115-22. 2003
    ..We investigated the potential for combined-modality therapy to increase the disease-free survival for such patients...
  28. ncbi request reprint Second malignancies after chemotherapy and radiotherapy for Hodgkin disease
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Am J Clin Oncol 27:73-80. 2004
    ..08). In an effort to reduce the risk of second malignancies, we have stopped using the alkylating agents nitrogen mustard and procarbazine and elective paraaortic and splenic radiotherapy after chemotherapy...
  29. ncbi request reprint Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center
    Qi Liu
    Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1582-9. 2006
    ..Advanced-stage follicular lymphoma is considered incurable. The pace of improvements in treatment has been slow. This article analyzes five sequential cohorts of patients with stage IV follicular lymphoma treated between 1972 and 2002...